PapersFlow Research Brief
Antibiotic Resistance in Bacteria
Research Guide
What is Antibiotic Resistance in Bacteria?
Antibiotic resistance in bacteria is the ability of bacterial populations to withstand the effects of antibiotics that would normally kill them or inhibit their growth, driven by mechanisms such as efflux pumps, plasmid-mediated resistance, carbapenemases, and extended-spectrum β-lactamases.
This field encompasses 136,494 published works on the emergence and spread of multidrug-resistant bacteria, including ESKAPE pathogens like Acinetobacter baumannii. Key mechanisms include plasmid-mediated colistin resistance such as MCR-1 and the role of efflux pumps in Gram-negative bacteria. Research addresses epidemiology, molecular biology, and antimicrobial resistance genes through standardized susceptibility testing and strain typing methods.
Topic Hierarchy
Research Sub-Topics
ESKAPE Pathogens
ESKAPE pathogens research targets Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species with multidrug resistance. Studies focus on their epidemiology, virulence, and therapeutic challenges.
Carbapenemases
Carbapenemases investigate enzymes hydrolyzing carbapenem antibiotics in Gram-negative bacteria, including KPC, NDM, and OXA types. Researchers study their genetics, spread, and inhibition strategies.
Plasmid-Mediated Resistance
Plasmid-mediated resistance examines horizontal gene transfer of resistance determinants like mcr-1 for colistin via plasmids. Work covers detection, transmission dynamics, and containment in bacteria.
Efflux Pumps
Efflux pumps research analyzes bacterial membrane proteins expelling antibiotics, contributing to intrinsic and acquired multidrug resistance. Studies target inhibitors and regulatory mechanisms.
Extended-Spectrum β-Lactamases
Extended-spectrum β-lactamases (ESBLs) focus on enzymes conferring resistance to third-generation cephalosporins in Enterobacteriaceae. Research includes molecular epidemiology, risk factors, and diagnostics.
Why It Matters
Antibiotic resistance causes substantial mortality, with Murray et al. (2022) estimating the global burden in 2019 through a systematic analysis that quantified deaths and disability-adjusted life years attributable to bacterial antimicrobial resistance. In the United States, the Centers for Disease Control and Prevention (2019) reported 48,700 annual deaths linked to antibiotic resistance or Clostridioides difficile. The Infectious Diseases Society of America highlighted infections resistant to all current antibacterials, particularly from gram-negative ESKAPE pathogens, as detailed in Boucher et al. (2008). Recent surveillance reports note nearly 400 antibiotic-resistant infections weekly in England in 2024, with 65% from E. coli bloodstream infections, while new consortia have secured $60 million for antibiotic discovery.
Reading Guide
Where to Start
"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically" by Ferraro (2000), as it provides foundational protocols essential for understanding resistance measurement before tackling mechanisms or epidemiology.
Key Papers Explained
Murray et al. (2022) quantify the global burden of bacterial antimicrobial resistance in 2019, building on definitions from Magiorakos et al. (2011) for multidrug-, extensively drug-, and pandrug-resistant bacteria. Davies and Davies (2010) trace origins and evolution, contextualizing mechanisms like those in Liu et al. (2015) on plasmid-mediated MCR-1 colistin resistance. Tacconelli et al. (2017) prioritize pathogens from these burdens, while Boucher et al. (2008) emphasize ESKAPE gaps.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints like "Global antibiotic resistance surveillance report 2025" highlight ongoing threats to treatments, with EARS-Net 2024 reporting high EU/EEA AMR levels and rising bloodstream infection incidences. News covers $60 million from Gates Foundation, Novo Nordisk, and Wellcome for novel antibiotic discovery consortia, plus CARB-X chemistry challenges for validated AMR targets.
Papers at a Glance
In the News
New Global Consortium Aims to Transform Antibiotic ...
### Philanthropic partners invest $60M to support collaborative research to accelerate the discovery of next-generation antibiotics
CARB-X announces new chemistry-focused theme ahead ...
*CARB-X Novel Chemistry for AMR Challenge seeks applications for validated AMR targets*
New global consortium aims to transform antibiotic discovery to counter the growing AMR crisis
The Gates Foundation, Novo Nordisk Foundation, and Wellcome today awarded a total of $60 million in new grant funding over the next three years to research teams around the world exploring novel ap...
PACE launches new funding for antimicrobial drug ...
# PACE launches new funding for antimicrobial drug development 3 October 2025
Antimicrobial resistance: What Canada's doing
We're also helping to fund global antimicrobial resistance initiatives. In May 2023, we invested $6.3 million in the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator. This inte...
Code & Tools
GeneBac is a modular framework for predicting antibiotic resistance in bacteria from DNA sequence.
A computational framework that assesses different machine learning algorithms ability to predict antibiotic resistance phenotype of bacterial strai...
### An R package to simplify the analysis and prediction of Antimicrobial Resistance (AMR) and work with antibiotic properties by using evidence-ba...
Antimicrobial resistance is one of the most pressing global health concerns, and machine learning algorithms can be a powerful tool in the fight ag...
Recent Preprints
Global antibiotic resistance surveillance report 2025
Antimicrobial resistance (AMR) is a growing threat to global health, undermining the effectiveness of life-saving treatments and placing populations at heightened risk, whether from common infectio...
Global antibiotic resistance surveillance report 2025: summary
Antimicrobial resistance (AMR) is a growing threat to global health, undermining the effectiveness of life-saving treatments and placing populations at heightened risk, whether from common infectio...
Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual epidemiological report for 2024
Overall antimicrobial resistance situation in the EU/EEA • Data from EARS-Net show that, as in previous years, AMR levels remained high in the EU/EEA in 2024. • Increases in the estimated EU/EEA i...
Annex 9. Table A9.1. Estimated percentage of AMR from the systematic review, 2018–2023 110 Foreword | v Foreword Antimicrobial resistance (AMR) is one of the 10 top global health threats, undermin...
Nearly 400 antibiotic-resistant infections each week in 2024
The English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) report shows that most antibiotic-resistant bloodstream infections in the last 6 years (65%) were caused by ...
Latest Developments
Recent research highlights four major advances in combating antibiotic resistance, including new approaches to stay ahead of resistant bacteria, the development of a new test that accurately measures bacterial killing by antibiotics, and insights into how resistance genes spread more widely between bacteria than previously thought (Washington Post, ScienceDaily). Additionally, 2025 saw a sharp rise in drug-resistant bacteria and stalled innovation in antibiotic discovery, emphasizing the urgent need for strategic research efforts (Clinical Leader, Nature).
Sources
Frequently Asked Questions
What are the standard definitions for multidrug-resistant, extensively drug-resistant, and pandrug-resistant bacteria?
Magiorakos et al. (2011) proposed interim standard definitions for acquired resistance in an international expert consensus. Multidrug-resistant bacteria are nonsusceptible to ≥1 agent in ≥3 antimicrobial categories, extensively drug-resistant to ≥1 agent in all but ≤2 categories, and pandrug-resistant to all agents in all categories tested. These definitions apply to bacteria that grow aerobically and aid in consistent global reporting.
How is antibiotic susceptibility tested for aerobic bacteria?
Ferraro (2000) detailed methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, serving as a standard reference with 16,886 citations. These methods establish minimum inhibitory concentrations to guide clinical decisions. They remain foundational for evaluating resistance in pathogens like ESKAPE bacteria.
What role do plasmids play in spreading colistin resistance?
Liu et al. (2015) identified the plasmid-mediated MCR-1 colistin resistance mechanism emerging in animals and humans in China through microbiological and molecular study. This gene transfers horizontally via plasmids, enabling rapid dissemination across bacterial populations. It exemplifies plasmid-mediated resistance contributing to multidrug resistance crises.
How are acquired antimicrobial resistance genes identified?
Zankari et al. (2012) developed ResFinder, a web server for identifying acquired antimicrobial resistance genes in sequenced bacterial isolates. It detects genes like those for carbapenemases and extended-spectrum β-lactamases from genomic data. The tool updates continuously with new resistance genes for epidemiological tracking.
What are ESKAPE pathogens?
Boucher et al. (2008) described ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species) as priority targets due to resistance evading available drugs. They cause infections resistant to all antibacterials, particularly gram-negative ones. Addressing them requires new antibiotics per WHO priority lists.
What is the WHO priority list for antibiotic-resistant bacteria?
Tacconelli et al. (2017) outlined the WHO priority list of antibiotic-resistant bacteria and tuberculosis to guide discovery and development of new antibiotics. It prioritizes critical pathogens like carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. The list directs research toward pathogens with high unmet needs.
Open Research Questions
- ? How do efflux pumps and carbapenemases interact to confer resistance in Gram-negative ESKAPE pathogens?
- ? What drives the evolution and global spread of plasmid-mediated resistance genes like MCR-1?
- ? Can standardized pulsed-field gel electrophoresis criteria reliably distinguish strain outbreaks amid rising resistance?
- ? Which new antibiotics target WHO priority multidrug-resistant bacteria lacking current options?
- ? How do environmental and animal reservoirs contribute to human antibiotic resistance burdens?
Recent Trends
EARS-Net data for 2024 show persistently high AMR levels in the EU/EEA with increases in resistant bloodstream infections, while the ESPAUR report notes nearly 400 antibiotic-resistant infections weekly in England, 65% from E. coli.
Preprints such as "Global antibiotic resistance surveillance report 2025" describe AMR as a top global health threat.
Funding trends include $60 million from the Gates Foundation, Novo Nordisk Foundation, and Wellcome for antibiotic discovery consortia in 2026 news.
Research Antibiotic Resistance in Bacteria with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Antibiotic Resistance in Bacteria with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers